An official website of the United States government
Home
Name
Trastuzumab
Alternate Names
Anti-c-erbB2 monoclonal antibody
Anti-erbB2 monoclonal antibody
Anti-HER2 monoclonal antibody
Anti-HER2/c-erbB2 monoclonal antibody
Anti-p185-HER2 monoclonal antibody
HER2 Mab
HER2 monoclonal antibody
HER2/neu Mab
HER2/neu monoclonal antibody
Herceptin
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Targeted therapy--epidermal growth factor receptor
NSC Number
688097
Primary Site
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Herceptin is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code Herceptin as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this as chemotherapy.
Phase II (breast, colorectal, lung) Phase III (ovarian, prostate)
Anti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI.
FDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarinoma who have not received prior treatment for metastatic disease.
Phase II (breast, colorectal, lung) Phase III (ovarian, prostate)
Anti HER-2 monoclonal antibody. FDA approved for use on breast cancer. Genentech, NCI.
FDA granted approval 10/2010 for Herceptin in combination with cisplatin and fluropyrimidine (either capecitabine or 5-FU) for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal (GE) junction adenocarinoma who have not received prior treatment for metastatic disease.
Coding
This drug should be coded
